Sonnet Biotherapeutics Holdings Inc Quick Ratio (SONN) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Sonnet Biotherapeutics Holdings Inc   (NASDAQ: SONN)

Sonnet Biotherapeutics Holdings Inc 's Quick Ratio

SONN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Sonnet Biotherapeutics Holdings Inc 's Cash & cash equivalent grew by 1493.62 % in the Q4 2025 sequentially, while Current Liabilities decreased, this led to improvement in Sonnet Biotherapeutics Holdings Inc 's Quick Ratio to 1.25, above Sonnet Biotherapeutics Holdings Inc average Quick Ratio.

Within Major Pharmaceutical Preparations industry 316 other companies have achieved higher Quick Ratio than Sonnet Biotherapeutics Holdings Inc in fourth quarter 2025. While Quick Ratio total ranking has improved so far during the Q4 2025 to 1383, from total ranking in the third quarter 2025 at 3111.

Explain Quick Ratio?
How much Cash & cash equivalents SONN´s has?
What are SONN´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SONN Quick Ratio (Sep 30 2025)
Q4		 (Jun 30 2025)
Q3		 (Mar 31 2025)
Q2		 (Dec 31 2024)
Q1		 (Sep 30 2024)
Q4
Y / Y Current Liabilities Change 27.62 % 64.05 % 14.81 % -41.89 % -41.89 %
Y / Y Cash & cash equivalent Change 3325.93 % -90.96 % -45.61 % -93.43 % -93.43 %
Quick Ratio MRQ 1.25 0.06 0.65 0.05 0.05
SONN's Total Ranking # 1383 # 3111 # 1904 # 1273 # 3427
Seq. Current Liabilities Change -19.7 % 60.73 % -1.12 % 0 % 3.23 %
Seq. Cash & cash equivalent Change 1493.62 % -84.4 % 1277.85 % 0 % -95.8 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 317
Healthcare Sector # 562
Overall Market # 1383


Quick Ratio Statistics
High Average Low
4.53 1.23 0.04
(Sep 30 2021)   (Mar 31 2012)




Financial Statements
Sonnet Biotherapeutics Holdings Inc 's Current Liabilities $ 4 Millions Visit SONN's Balance sheet
Sonnet Biotherapeutics Holdings Inc 's Cash & cash equivalent $ 5 Millions Visit SONN's Balance sheet
Source of SONN's Sales Visit SONN's Sales by Geography


Cumulative Sonnet Biotherapeutics Holdings Inc 's Quick Ratio

SONN's Quick Ratio for the trailling 12 Months

SONN Quick Ratio

 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months		 (Dec 31 2024)
12 Months		 (Sep 30 2024)
12 Months
Y / Y Current Liabilities TTM Growth 6.67 % -13.16 % -37.35 % -51.38 % -47.69 %
Y / Y Cash & cash equivalent TTM Growth -21.65 % -77.46 % -61.5 % -66.73 % -58.87 %
Quick Ratio TTM 0.49 0.18 0.47 0.62 0.67
Total Ranking TTM # 3219 # 2882 # 3239 # 3554 # 3525
Seq. Current Liabilities TTM Growth 6.03 % 15.68 % 3.33 % -15.84 % -13.68 %
Seq. Cash & cash equivalent TTM Growth 185.51 % -54.68 % -22.61 % -21.76 % -17.87 %

Quick ratio ranking by company, industry and sector >> Back to SONN Financial Strength Comparisons >> Go to Compare SONN Quick Ratio to its Competitors

On the trailing twelve months basis SONN Cash & cash equivalent more than doubled by 3325.93 % in Q4 2025 year on year, faster than Current Liabilities, this led to increase in in Sonnet Biotherapeutics Holdings Inc 's Quick Ratio to 0.49, Quick Ratio remained below SONN average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 419 other companies have achieved higher Quick Ratio than Sonnet Biotherapeutics Holdings Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from 2882 to 3219.

Explain Quick Ratio?
How much Cash & cash equivalents SONN´s has?
What are SONN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 420
Healthcare Sector # 868
Within the Market # 3219


trailing twelve months Quick Ratio Statistics
High Average Low
3 1.31 0.51
(Dec 31 2021)   (Jun 30 2025)




Companies with similar Quick Ratio in the quarter ending Sep 30 2025, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2025 MRQ Cash & cash equivalentSep 30 2025 MRQ Current Liabilities
Tvardi Therapeutics Inc   3.34 $ 36.460  Millions$ 10.927  Millions
Kyntra Bio Inc   3.28 $ 117.975  Millions$ 35.973  Millions
Immunoprecise Antibodies Ltd   3.23 $ 11.983  Millions$ 3.705  Millions
Arrowhead Pharmaceuticals Inc   3.20 $ 692.818  Millions$ 216.286  Millions
Bolt Biotherapeutics Inc   3.20 $ 31.910  Millions$ 9.966  Millions
Elicio Therapeutics Inc   3.16 $ 20.611  Millions$ 6.515  Millions
Tempest Therapeutics Inc   3.16 $ 7.514  Millions$ 2.378  Millions
Can fite Biopharma Ltd   3.13 $ 8.540  Millions$ 2.731  Millions
Pasithea Therapeutics Corp   3.08 $ 4.123  Millions$ 1.338  Millions
Nuvectis Pharma inc   3.08 $ 35.442  Millions$ 11.502  Millions
Briacell Therapeutics Corp   3.07 $ 10.176  Millions$ 3.318  Millions
Biomea Fusion Inc   3.00 $ 46.642  Millions$ 15.565  Millions
Bridgebio Pharma Inc   2.98 $ 645.942  Millions$ 216.600  Millions
Adagene Inc   2.96 $ 74.524  Millions$ 25.172  Millions
Insmed Inc  2.93 $ 1,679.986  Millions$ 573.689  Millions
Ardelyx inc   2.91 $ 242.705  Millions$ 83.389  Millions
Gossamer Bio Inc   2.90 $ 180.224  Millions$ 62.117  Millions
Damora Therapeutics Inc   2.90 $ 7.606  Millions$ 2.623  Millions
Lipella Pharmaceuticals Inc   2.89 $ 1.856  Millions$ 0.642  Millions
Cadrenal Therapeutics Inc  2.85 $ 3.860  Millions$ 1.353  Millions
Clearside Biomedical Inc   2.85 $ 6.801  Millions$ 2.386  Millions
Kiniksa Pharmaceuticals International Plc  2.85 $ 352.102  Millions$ 123.592  Millions
Proqr Therapeutics N v   2.85 $ 103.503  Millions$ 36.334  Millions
Madrigal Pharmaceuticals Inc   2.84 $ 1,109.749  Millions$ 390.323  Millions
Geovax Labs Inc   2.75 $ 5.009  Millions$ 1.824  Millions
Schrodinger Inc   2.70 $ 391.233  Millions$ 145.113  Millions
Relmada Therapeutics Inc  2.68 $ 13.887  Millions$ 5.190  Millions
Actuate Therapeutics Inc   2.66 $ 16.925  Millions$ 6.373  Millions
Bullfrog Ai Holdings Inc   2.62 $ 1.991  Millions$ 0.759  Millions
Indaptus Therapeutics Inc   2.62 $ 5.826  Millions$ 2.226  Millions

Date modified: 2026-08-29T07:16:11+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.